UNIQUE EXPERTISE
Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
UNIQUE CAPABILITIES
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
OUR PUBLICATIONS
We regularly publish our discoveries in major, peer-reviewed journals, enabling others to further validate and expand upon our findings.
NEWS
deCODE and Merck Form Landmark Alliance in Obesity
Alliance brings together world-leading capabilities in genetics and drug development to speed the discovery of new treatments Reykjavik, ICELAND, September 27, 2002 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) and Merck & Co., Inc. (NYSE:MRK) today announced the...
deCODE Publishes Landmark Study Linking the Neuregulin 1 Gene to Schizophrenia
Research yields promising drug targets impacting underlying biology of the disease; Findings form the basis of deCODE’s most advanced drug discovery program Reykjavik, ICELAND, July 24, 2002 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) today announced the publication...
Award by the American Society of Human Genetics
At its Annual meeting in October 2017 in Orlando, the American Society of Human Genetics (ASHG), presented Dr. Kári Stefánsson, founder and CEO of deCODE genetics, with the William Allan Award. The award, the top prize given by the society, recognizes a scientist for substantial and far-reaching scientific contributions to human genetics. The ASHG has distributed video footage from the award ceremony. The introduction is given by Professor Mark Daly of Harvard University.